Novo’s next-gen obesity drug stumbles in Lilly comparison study

STAT·Feb 23

This story is reported by STAT. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

Novo Nordisk’s next-gen obesity drug stumbles in comparison study

STAT·Feb 23

2

Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study

BioPharma Dive·Feb 23

3

Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly

Reuters·Feb 23

4

Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial

CNBC·Feb 23

5

Novo Next-Generation Obesity Shot Falls Short of Lilly Rival

Bloomberg.com·Feb 23

6

Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound

WSJ·Feb 23

7

Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial

Yahoo! Finance Canada·Feb 23

8

Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin

Investor's Business Daily·Feb 23